Avacta Group Plc (LON:AVCT) had its Corporate rating reiterated by FinnCap

Analyst Ratings For Avacta Group Plc (LON:AVCT)

Story continues below

Today, FinnCap reiterated its Corporate rating on Avacta Group Plc (LON:AVCT).

There are 0 Strong Buy Ratings, no Sell Ratings, no Hold Ratings, no Buy Ratings on the stock.

The current consensus rating on Avacta Group Plc (LON:AVCT) is N/A with a consensus target price of GBX 200 per share, a potential .

Some recent analyst ratings include

  • 1/21/2019-Avacta Group Plc (LON:AVCT) had its Corporate rating reiterated by FinnCap
  • 4/4/2017-Avacta Group Plc (LON:AVCT) had its Buy rating reiterated by Numis Securities with a GBX 160 price target

    About Avacta Group Plc (LON:AVCT)
    Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. It operates through two segments, Life Sciences and Animal Health. The company's custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development. In addition, it provides tools and contract services to assist the diagnosis of conditions in animals to enable treatment for veterinarians. The company has a collaboration, licensing, and option agreement with Moderna Therapeutics; research collaboration with OncoSec Medical Incorporated for gene delivery of therapeutic Affimers; and a co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

    Recent Trading Activity for Avacta Group Plc (LON:AVCT)
    Shares of Avacta Group Plc closed the previous trading session at 38,35 +0,95 2,54 % with shares trading hands.

    An ad to help with our costs